The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881

Atherosclerosis

Volumn 144, Issue 2, 1999, Pages 343-355

  Feldman, David L ^a   Mogelesky, Therese C ^a   Sharif, Robin ^a   Sawyer, W Kit ^a   Jeune, Michael ^a   Hu, Chii Whei ^a   Leonards, Kenneth S ^a   Forney Prescott, Margaret ^a  

^a US Research Department   (United States)

Author keywords

Antioxidant; CGP 2881; Hypolipidemic; Oxidized LDL; Probucol

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; CGP 2881; CHOLESTEROL; LIPOPROTEIN; PROBUCOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CHOLESTEROL; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MICE; OXIDATION-REDUCTION; PROBUCOL; RABBITS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033011077     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00002-7     Document Type: Article

References (48)

1. Steinberg D., Pathasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
2. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad. Biol. Med. 13:1992;341-390.
3. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. 84:1987;7725-7729.
4. Kita T., Nagano Y., Yokode M., Ishi K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. 84:1987;5928-5931.
5. Yla-Hertualla S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions in rabbit and man. J. Clin. Invest. 84:1989;1086-1095.
6. Sparrow C.P., Doebber T.W., Olszewski J., Wu M.S., Ventre J., Stevens K.A., Chaos Y.S. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine. J. Clin. Invest. 89:1992;1885-1891.
7. Sasahara M., Raines E.W., Chait A., Carew T.E., Steinberg D., Wahl P.W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. J. Clin. Invest. 94:1994;155-164.
8. Gey K.F., Puska P., Jordan P., Moser U.K. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am. J. Clin. Nutr. 53:1991;326S-334S.
9. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary disease in men. N. Engl. J. Med. 328:1993;1450-1456.
10. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 328:1993;1444-1449.
11. Salonen J.T., Yla-Hertualla S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
12. Chiu H.C., Jeng J.R., Shieh S.M. Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Biochim. Biophys. Acta. 1225:1994;200-208.
13. Maggi E., Chiesa R., Melissano G., Castellano R. LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14:1994;1892-1899.
14. Markwell A.K., Haas S.M., Bieber L.L., Tolbert N.E. Modification of Lowry procedure to simplify protein determinations in membranes and lipoprotein samples. Anal. Biochem. 87:1978;206-210.
15. Esterbauer H., Striegl G., Puhl H., Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad. Res. Commun. 6:1989;67-75.
16. Morel D., DiCorleto P.E., Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Atherosclerosis. 4:1984;357-364.
17. Meltzer M.S. Peritoneal mononuclear phagocytes from small animals. Adams D.O., Edelson P.J., Koren H.S. Methods for Studying Mononuclear Phagocytes. 1981;63-67 Academic Press, New York.
18. Janero D.R. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Rad. Biol. Med. 9:1990;515-540.
19. Jialal I.J., Freeman D.A., Grundy S.M. Varying susceptibility of different low density lipoproteins to oxidative modification. Arterio Thromb. Vasc. Biol. 11:1991;482-488.
20. Esterbauer H., Puhl H., Rotheneder-Diebe M., Waeg G., Rabl H. Effect of antioxidants on oxidative modification of LDL. Ann. Med. 23:1991;573-581.
21. Esterbauer H., Rotheneder-Dieber M., Striegl G., Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am. J. Clin. Nutr. 53:1991;314S-321S.
22. Barnhart R.L., Busch S.J., Jackson R.L. Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro: probucol degradation precedes lipoprotein oxidation. J. Lipid Res. 30:1989;1703-1710.
23. SAS/STAT Users Guide, Version 6, Fourth Edition, SAS Institute, Cary, NC, 1989, p. 1686.
24. Fruebis J., Steinberg D., Dresel H.A., Carew T.E. A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J. Clin. Invest. 94:1994;392-398.
25. Reaven P.D., Parthasarathy S., Beltz W.F., Witztum J.L. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler. Thromb. 12:1991;318-324.
26. Esterbauer H., Rotheneder-Dieber M., Striegl G., Waeg G. Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am. J. Clin. Nutr. 53:1991;314S-321S.
27. Jialal I., Fuller C.J., Huet B.A. The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler. Thromb. Vasc. Biol. 15:1995;190-198.
28. Jackson R.L., Barnhart R.L., Mao S.J.T. Probucol and its mechanisms for reducing atherosclerosis. Adv. Exp. Med. Biol. 285:1991;367-372.
29. Gotoh N., Shimizu K., Komuro E., Tsuchiya J., Noguchi N., Niki E. Antioxidant activities of probucol against lipid peroxidations. Biochim. Biophys. Acta. 1128:1992;147-154.
30. Pryor W.A., Strickland T., Church D.F. Comparison of the efficiencies of several natural and synthetic antioxidants in aqueous sodium dodecyl sulfate micelle solutions. J. Am. Chem. Soc. 110:1988;2224-2229.
31. Darley-Usmar V.M., Hersey A., Garland L.G. A method for the comparative assessment of antioxidants as peroxyl radical scavengers. Biochem. Pharmacol. 38:1989;1465-1469.
32. Kagan V.E., Freisleben H.J., Tsuchiya M., Forte T., Packer L. Generation of probucol radicals and their reduction by ascorbate and dihydrolipoic acid in human low density lipoproteins. Free Rad. Res. Commun. 15:1991;265-276.
33. Kalyanaraman B., Darley-Usmarm V.M., Wood J., Joseph J., Parthasarathy S. Synergistic interaction between the probucol phenoxyl radical and ascorbic acid in inhibiting the oxidation of low density lipoprotein. J. Biol. Chem. 267:1992;6789-6795.
34. Niki E. Antioxidants in relation to lipid peroxidation. Chem. Phys. Lipids. 44:1987;227-253.
35. Parthasarathy S. Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative. J. Clin. Invest. 89:1992;1618-1621.
36. Parthasarathy S., Printz D.J., Boyd D., Joy L., Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 6:1986;505-510.
37. Hiramatsu K., Rosen H., Heinecke J.W., Wolfbauer G., Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arterio Thromb. 7:1987;55-60.
38. Leake D.S., Rankin S.M. The oxidative modification of low-density lipoproteins by macrophages. Biochem. J. 270:1990;741-748.
39. Nenseter M.S., Gudmundsen O., Malterud K.E., Berg T., Drevon C.A. Effect of cholesterol feeding on the susceptibility of lipoproteins to oxidative modification. Biochim. Biophys. Acta. 1213:1994;207-214.
40. Thomas C.E., Jackson R.L. Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low density lipoproteins. J. Pharmacol. Exper. Ther. 256:1991;1182-1188.
41. Frei B., Gaziano J.M. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. J. Lipid Res. 34:1993;2135-2145.
42. Bitman J., Weyant J., Wood D.L., Wrenn T.R. Vitamin E, cholesterol, and lipids during atherogenesis in rabbits. Lipids. 11:1976;449-461.
43. Parthasarathy S., Khoo J.C., Miller E., Barnett J., Witztum J.L., Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: Implications for dietary prevention of atherosclerosis. Proc. Natl. Acad. Sci. 87:1990;3894-3898.
44. de Graaf J., Hak-Lemmers H.L.M., Hectors M.P.C., Demacker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:1991;298-306.
45. Bonanome A., Pagnan A., Biffanti S., Opportuno A., Sorgato F., Dorella M., Maiorino M., Ursini F. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler. Thromb. 12:1992;529-533.
46. Scaccini C., Nardini M., D'Aquino M., Gentili V., Di Felice M., Tomassi G. Effect of dietary oils on lipid peroxidation and on antioxidant parameters of rat plasma and lipoprotein fractions. J. Lipids Res. 33:1992;627-633.
47. Kleinveld H.A., Naber A.H.J., Stalenhoef A.F.H., Demacker P.N.M. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects. Free Rad. Biol. Med. 15:1993;273-280.
48. Cominacini L., Pastorino A.M., Garbin U., Campagnola M., De Santis A., Davoli, Faccini G., Bertozzo L., Pasini F., Pasini A.F., Lo Cascio V. The susceptibility of low-density lipoprotein to in vitro oxidation is increased in hypercholesterolemic patients. Nutrition. 10:1994;527-531.